From the Discipline of Occupational Therapy, School of Health Science and Social Work, Griffith University; and Occupational Therapy Department, Queen Elizabeth II Jubilee Hospital, Metro South Hospital and Health Service.
Plast Reconstr Surg. 2022 Apr 1;149(4):913-917. doi: 10.1097/PRS.0000000000008959.
Collagenase injection is a relatively new, minimally invasive treatment option for Dupuytren disease. Most literature focusses on quantitative outcome measures, such as degree of residual contracture and recurrence. The patient experience of the treatment has rarely been explored. This study sought to explore patients' experiences of the treatment process, including their reasons for seeking and choosing the treatment.
A qualitative descriptive design was used to explore patients' experiences. Seven patients (aged 57 to 81 years) who had received collagenase treatment for Dupuytren disease engaged in individual, semistructured interviews. Interviews were audio recorded, transcribed verbatim, and analyzed thematically.
Thematic analysis revealed that Dupuytren disease was an obstacle to doing things, but not a barrier. Patients "went with the flow" of treatment, often taking a passive approach to their health care decisions. Patients found the collagenase injections to be extremely painful, but worth it. They had a varied knowledge of the disease and treatment.
Patients were pleased with the results of the collagenase treatment, even if the finger was not completely straight or there was recurrence. The quick recovery and minimal complications were positive factors; however, the injections were extremely painful and could deter patients from future treatment. This research highlighted that a number of patients had low health literacy regarding their condition, and this affected their expectations of treatment outcomes and future treatment seeking. There are opportunities for health professionals to improve health literacy for people with Dupuytren disease, possibly in a group setting.
胶原酶注射是一种相对较新的、微创的治疗方法，用于治疗掌腱膜挛缩症。大多数文献都集中在定量的结果测量上，如残余挛缩程度和复发率。该治疗方法的患者体验很少被探索过。本研究旨在探讨患者对治疗过程的体验，包括他们寻求和选择治疗的原因。
采用定性描述性设计来探索患者的体验。7 名（年龄 57 至 81 岁）接受过胶原酶治疗的掌腱膜挛缩症患者参与了个体半结构化访谈。访谈进行了录音，并逐字转录，然后进行主题分析。
主题分析显示，掌腱膜挛缩症是做事的障碍，但不是障碍。患者“顺其自然”地接受治疗，通常对自己的医疗保健决策采取被动态度。患者发现胶原酶注射非常疼痛，但值得。他们对疾病和治疗有不同的认识。
患者对胶原酶治疗的结果感到满意，即使手指没有完全伸直或有复发。快速康复和最小的并发症是积极因素；然而，注射非常疼痛，可能会阻止患者接受未来的治疗。这项研究强调，许多患者对自己的病情健康素养较低，这影响了他们对治疗结果和未来治疗需求的期望。为掌腱膜挛缩症患者提供健康教育的机会可能在小组环境中。
